| scholarly article | Q13442814 |
| P50 | author | Steven Opal | Q117793560 |
| P2093 | author name string | Mark Tidswell | |
| Steven P Larosa | |||
| Richard Kao | |||
| Melvyn Lynn | |||
| Jagadish Gogate | |||
| William Tillis | |||
| Alec E Wittek | |||
| Janice Wheeler | |||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | sepsis | Q183134 |
| patient | Q181600 | ||
| toll-like receptor | Q408004 | ||
| phase II clinical trial | Q42824440 | ||
| P304 | page(s) | 72-83 | |
| P577 | publication date | 2010-01-01 | |
| P1433 | published in | Critical Care Medicine | Q5186605 |
| P1476 | title | Phase 2 trial of eritoran tetrasodium (E5564), a toll-like receptor 4 antagonist, in patients with severe sepsis | |
| P478 | volume | 38 |
| Q39622833 | A novel aminosaccharide compound blocks immune responses by Toll-like receptors and nucleotide-binding domain, leucine-rich repeat proteins |
| Q37058796 | A novel imidazopyridine derivative, X22, attenuates sepsis-induced lung and liver injury by inhibiting the inflammatory response in vitro and in vivo |
| Q85716911 | Animal models of sepsis |
| Q27675263 | Antibody WN1 222-5 mimics Toll-like receptor 4 binding in the recognition of LPS |
| Q50220864 | Association of the TLR4 signaling pathway in the retina of streptozotocin-induced diabetic rats |
| Q37973108 | Bench-to-bedside review: Damage-associated molecular patterns in the onset of ventilator-induced lung injury |
| Q97525823 | Biomarkers and Associated Immune Mechanisms for Early Detection and Therapeutic Management of Sepsis |
| Q40086314 | Bolstering Immunity through Pattern Recognition Receptors: A Unique Approach to Control Tuberculosis |
| Q37003067 | Combined Inhibition of Complement and CD14 Attenuates Bacteria-Induced Inflammation in Human Whole Blood More Efficiently Than Antagonizing the Toll-like Receptor 4-MD2 Complex. |
| Q45895881 | Determination of the safety and efficacy of therapeutic neutralization of tumor necrosis factor-α (TNF-α) using AZD9773, an anti-TNF-α immune Fab, in murine CLP sepsis |
| Q34672043 | Developing the next generation of monoclonal antibodies for the treatment of rheumatoid arthritis |
| Q95495215 | Drotrecogin alfa (activated) in severe sepsis |
| Q38193705 | Dynamics of pulmonary endothelial barrier function in acute inflammation: mechanisms and therapeutic perspectives |
| Q90643005 | Dysbiosis of Gram-negative gut microbiota and the associated serum lipopolysaccharide exacerbates inflammation in type 2 diabetic patients with chronic kidney disease |
| Q30300333 | Emerging therapeutic targets of sepsis-associated acute kidney injury |
| Q47743545 | Endotoxin Preconditioning Reprograms S1 Tubules and Macrophages to Protect the Kidney |
| Q34726541 | Eritoran tetrasodium (E5564) treatment for sepsis: review of preclinical and clinical studies |
| Q97536422 | FDA Approved Drugs Repurposing of Toll-Like Receptor4 (TLR4) Candidate for Neuropathy |
| Q35657133 | From agonist to antagonist: structure and dynamics of innate immune glycoprotein MD-2 upon recognition of variably acylated bacterial endotoxins |
| Q26864635 | Host innate immune responses to sepsis |
| Q27016140 | How the Innate Immune System Senses Trouble and Causes Trouble |
| Q33724228 | Identification of potential biomarkers of sepsis using bioinformatics analysis |
| Q37960531 | Immune-modulating interventions in critically ill septic patients: pharmacological options |
| Q22305766 | Immunomodulation in sepsis: state of the art and future perspective |
| Q26830445 | Immunomodulation in sepsis: the role of endotoxin removal by polymyxin B-immobilized cartridge |
| Q37949639 | Immunomodulatory therapy for sepsis: an update |
| Q38557048 | Inhibition of Toll-Like Receptor Signaling as a Promising Therapy for Inflammatory Diseases: A Journey from Molecular to Nano Therapeutics |
| Q37761419 | Innate immunity and rheumatoid arthritis |
| Q26860007 | Interferon induction by RNA viruses and antagonism by viral pathogens |
| Q58781575 | Lipid A: Immunological Properties and Molecular Basis of Its Binding to the Myeloid Differentiation Protein-2/Toll-Like Receptor 4 Complex |
| Q38662525 | Lipopolysaccharide inhibits myogenic differentiation of C2C12 myoblasts through the Toll-like receptor 4-nuclear factor-κB signaling pathway and myoblast-derived tumor necrosis factor-α |
| Q36693987 | Micheliolide inhibits LPS-induced inflammatory response and protects mice from LPS challenge |
| Q35017599 | Modeling Human Respiratory Viral Infections in the Cotton Rat (Sigmodon hispidus). |
| Q37994068 | Modulating immunity as a therapy for bacterial infections |
| Q37805517 | Modulation of toll-like receptor function has therapeutic potential in autoimmune disease |
| Q35743018 | Monocyte Tumor Necrosis Factor-α-Converting Enzyme Catalytic Activity and Substrate Shedding in Sepsis and Noninfectious Systemic Inflammation |
| Q35821157 | Pancreatic Perfusion CT in Early Stage of Severe Acute Pancreatitis |
| Q37849200 | Peptide-based treatment of sepsis |
| Q38823721 | Physiological aspects of Toll-like receptor 4 activation in sepsis-induced acute kidney injury |
| Q37989884 | Prophylactic and therapeutic implications of toll-like receptor ligands |
| Q34309172 | Renal effects of treatment with a TLR4 inhibitor in conscious septic sheep. |
| Q42412734 | Risk of death and the efficacy of eritoran tetrasodium (E5564): design considerations for clinical trials of anti-inflammatory agents in sepsis |
| Q38084202 | Role of the Toll Like receptor (TLR) radical cycle in chronic inflammation: possible treatments targeting the TLR4 pathway |
| Q37854080 | Role of toll-like receptors in cardiovascular diseases |
| Q36470840 | SYSTEM-WIDE MAPPING OF ACTIVATED CIRCUITRY IN EXPERIMENTAL SYSTEMIC INFLAMMATORY RESPONSE SYNDROME. |
| Q38326541 | Safety, pharmacokinetics and pharmacodynamics of four-hour intravenous infusions of eritoran in healthy Japanese and Caucasian men. |
| Q38695565 | Screening Bioactive Nanoparticles in Phagocytic Immune Cells for Inhibitors of Toll-like Receptor Signaling. |
| Q57281918 | Screening of herbal extracts for TLR2- and TLR4-dependent anti-inflammatory effects |
| Q38050487 | Sensing of microbial molecular patterns by Toll-like receptors |
| Q30251753 | Sepsis: in search of cure. |
| Q37655890 | Sepsis: multiple abnormalities, heterogeneous responses, and evolving understanding |
| Q42679358 | Statistical analysis plan of PROWESS SHOCK study. |
| Q43016666 | Stopping sepsis by targeting sphingosine kinase 1. |
| Q34436905 | Strategies to improve drug development for sepsis |
| Q26823892 | T-cell-mediated immunity and the role of TRAIL in sepsis-induced immunosuppression |
| Q48641496 | TLR4 Signaling Pathway Modulators as Potential Therapeutics in Inflammation and Sepsis |
| Q37693395 | Targeting myeloid differentiation protein 2 by the new chalcone L2H21 protects LPS-induced acute lung injury |
| Q37896347 | Targeting of Toll-like receptors: a decade of progress in combating infectious diseases |
| Q89060807 | Targeting toll-like receptor-4 (TLR4)-an emerging therapeutic target for persistent pain states |
| Q27010345 | Targeting toll-like receptors: promising therapeutic strategies for the management of sepsis-associated pathology and infectious diseases |
| Q90421576 | The Inhibitory Role of M2000 (β-D-Mannuronic Acid) on Expression of Toll-like Receptor 2 and 4 in HT29 Cell Line |
| Q48244517 | The Role of Danger Signals in the Pathogenesis and Perpetuation of Critical Illness |
| Q37051987 | The TLR4 antagonist Eritoran protects mice from lethal influenza infection |
| Q26745749 | The emerging role of Toll-like receptor 4 in myocardial inflammation |
| Q36469613 | The evolving experience with therapeutic TNF inhibition in sepsis: considering the potential influence of risk of death |
| Q38246131 | The immune response and antibacterial therapy. |
| Q37991392 | The immune response to severe bacterial infections: consequences for therapy |
| Q45811531 | The molecular basis of the host response to lipopolysaccharide |
| Q36934401 | The pathogenesis of sepsis. |
| Q42752509 | Therapeutic strategies in inflammasome mediated diseases of the liver |
| Q26795636 | Therapeutic strategies in pneumonia: going beyond antibiotics |
| Q36453194 | Toll-like Receptors in the Vascular System: Sensing the Dangers Within |
| Q37731959 | Toll-like receptor 4 modulation as a strategy to treat sepsis |
| Q37879190 | Toll-like receptor-4 antagonist eritoran tetrasodium for severe sepsis |
| Q39584513 | Toll-like receptors and opportunities for new sepsis therapeutics |
| Q37850809 | Toll-like receptors as potential therapeutic targets in cardiac dysfunction |
| Q36940639 | Toll-like receptors as therapeutic targets for autoimmune connective tissue diseases |
| Q38082543 | Toll-like receptors in neonatal sepsis |
| Q38174528 | Toll-like receptors: Role in inflammation and therapeutic potential |
| Q26996658 | Towards clinical applications of anti-endotoxin antibodies; a re-appraisal of the disconnect |
| Q35658313 | Translational research in sepsis - an ultimate challenge? |
| Q33722712 | Western diet enhances hepatic inflammation in mice exposed to cecal ligation and puncture |
| Q39543522 | What is next in sepsis: current trials in sepsis |
Search more.